Test PegINFa after bone marrow transplant for myelofibrosis
Part of Blood & lymphatic clinical trials.
This Phase 1 study tests PegINFa (after a bone marrow transplant) to see if it is safe and can help control myelofibrosis. You must be eligible for transplant and meet specific donor, timing, and health criteria before starting the study drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 or older
- Have primary or secondary myelofibrosis
- Be able to get a bone marrow transplant using either reduced-intensity or higher-intensity preparation (myeloablative or reduced intensity)
- Have a 10/10 matched donor (related or unrelated) and a blood stem cell graft from the bloodstream (PBSC)
- Be in good enough shape for study participation (ECOG 0–2)
- Be able to meet pregnancy prevention rules (and, if applicable, condom use during study treatment)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a type of interferon (ropeginterferon) to your current myelofibrosis treatment (ruxolitinib) is safe and tolerable. Myelofibrosis is a blood disorder where bone marrow becomes scarred; this combination might help control the disease better.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This trial studies whether an allogeneic (donor) stem cell transplant can help people with higher-risk myelofibrosis (fibrosis in the bone marrow). It looks at outcomes in different donor types as determined by matching rules and patient risk level.
This trial tests a combination of two oral medications for people with myelofibrosis, a type of bone marrow cancer. It may be an option if you have not been helped by standard JAK inhibitor therapy or if you have never tried one.
This trial tests whether the drug momelotinib, given before and after a stem cell transplant (also called a bone marrow transplant), can help people with myelofibrosis. The hope is that it will make the transplant safer and more effective.
This trial tests two oral medications, momelotinib and ruxolitinib, to see which works better for people with newly diagnosed myelofibrosis who also have low blood cell counts. You may be able to join if your spleen is enlarged and you haven't had prior treatment with certain drugs.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.